Latest Financial Results News

Australian Unity Limited reported robust FY2025 financial results, driven by strategic acquisitions and ongoing transformation efforts, returning to profitability with a $26.6 million net profit. The company is poised to complete its multi-year transformation by year-end and focus on growth amid rising demand for aged care and health services.

Nido Education Limited reported an 8% rise in Service EBITDA to $12.8 million for the first half of 2025, maintaining steady operational performance despite sector-wide occupancy challenges. The company declared a fully franked interim dividend of 1.5 cents per share, underscoring confidence in its growth strategy.

Nido Education Limited reported a 7.5% increase in revenue for the half-year ending June 2025, alongside a modest net profit and a fully franked interim dividend. The company also completed a strategic acquisition to expand its childcare footprint.

Platinum Asset Management reports improved FY2025 financials alongside a transformative merger proposal with L1 Capital, aiming to create a $16.5 billion alternative asset manager.

Australian Unity Limited reports a strong FY2025 financial turnaround with $136.2 million Adjusted EBITDA, driven by a multi-year transformation program focused on portfolio reshaping and technology integration.

Platinum Asset Management reported a sharp 86% drop in profit for FY25, driven by a 39% decline in funds under management amid sustained outflows and investment challenges. The company announced a transformative merger with L1 Capital, aiming to create a $16.5 billion asset manager.

GenusPlus Group Ltd has delivered record FY2025 financial results, driven by strong contract wins and strategic acquisitions, positioning itself as a key player in Australia’s energy transition. The company forecasts robust earnings growth for FY2026 backed by a $2 billion orderbook.

Imagion Biosystems reported a $1.66 million loss for the half-year ending June 2025 while progressing its MagSense® HER2 Imaging Agent towards a Phase 2 FDA trial and securing $3.5 million in new funding.

Nova Eye Medical has delivered solid FY25 results, meeting sales guidance outside China and achieving six consecutive halves of growth in the US market. The company also improved gross margins and reduced cash burn, setting an optimistic tone for FY26 with breakeven EBITDA guidance.

Nova Eye Medical has reported a record A$29.3 million in FY25 revenue, driven by sustained US growth and operational improvements, setting the stage for breakeven EBITDA in the first half of FY26.

Nova Eye Medical Limited reported a 25% increase in revenue to AUD 29.3 million for FY2025, driven by strong sales in its glaucoma surgical devices segment, yet posted a net loss after tax of AUD 9.1 million. The company raised AUD 6.2 million through a share placement to support growth initiatives.

Mesoblast Limited is set to release its full-year financial results and operational highlights for 2025, spotlighting its FDA-approved cell therapy and expanding global partnerships.